The Safety of Soy Leghemoglobin Protein Preparation Derived from Pichia pastoris Expressing a Soy Leghemoglobin Gene from Glycine max: In Vitro and In Vivo Studies
Soy leghemoglobin (LegH) protein derived from soy (Glycine max) produced in Pichia pastoris (reclassified as Komagataella phaffii) as LegH Prep is a novel food ingredient that provides meat-like flavor and aroma to plant-derived food products. The safety of LegH Prep has been previously assessed in...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-01-01
|
| Series: | Journal of Toxicology |
| Online Access: | http://dx.doi.org/10.1155/2023/7398724 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849685966474706944 |
|---|---|
| author | Teresa F. Reyes Puja Agrawal Teresa Chan Richard Green Ray A. Matulka |
| author_facet | Teresa F. Reyes Puja Agrawal Teresa Chan Richard Green Ray A. Matulka |
| author_sort | Teresa F. Reyes |
| collection | DOAJ |
| description | Soy leghemoglobin (LegH) protein derived from soy (Glycine max) produced in Pichia pastoris (reclassified as Komagataella phaffii) as LegH Prep is a novel food ingredient that provides meat-like flavor and aroma to plant-derived food products. The safety of LegH Prep has been previously assessed in a battery of in vivo and in vitro testing and found no adverse effects under the conditions tested. In this new work, we present the results of new in vivo and in vitro tests evaluating the safety of LegH Prep. LegH Prep was nonmutagenic in a bacterial reverse mutation assay and nonclastogenic in an in vitro micronucleus assay in human lymphocytes. Systemic toxicity was evaluated in the 90 day dietary study in male and female Sprague–Dawley® rats that included a 28 day recovery period. The study resulted in no animal deaths associated with the administration of LegH Prep at the highest dose (90,000 ppm). There were no significant adverse clinical or physical changes attributed to LegH Prep administration, and no observed adverse effects on either male or female rats over the course of the 28 day recovery phase study. The new 90 day dietary toxicity study established a no observed adverse effect level (NOAEL) of 4798.3 and 5761.5 mg/kg/day, the maximum level tested for male and female rats, respectively. Thus, the results of the studies demonstrate that under the conditions tested, LegH Prep is not toxic for consumption in meat analog products. |
| format | Article |
| id | doaj-art-bbfba3f03cbb48e0a4ac90fa192e6fe2 |
| institution | DOAJ |
| issn | 1687-8205 |
| language | English |
| publishDate | 2023-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Toxicology |
| spelling | doaj-art-bbfba3f03cbb48e0a4ac90fa192e6fe22025-08-20T03:22:53ZengWileyJournal of Toxicology1687-82052023-01-01202310.1155/2023/7398724The Safety of Soy Leghemoglobin Protein Preparation Derived from Pichia pastoris Expressing a Soy Leghemoglobin Gene from Glycine max: In Vitro and In Vivo StudiesTeresa F. Reyes0Puja Agrawal1Teresa Chan2Richard Green3Ray A. Matulka4Impossible Foods Inc.Impossible Foods Inc.Impossible Foods Inc.Impossible Foods Inc.Burdock Group ConsultantsSoy leghemoglobin (LegH) protein derived from soy (Glycine max) produced in Pichia pastoris (reclassified as Komagataella phaffii) as LegH Prep is a novel food ingredient that provides meat-like flavor and aroma to plant-derived food products. The safety of LegH Prep has been previously assessed in a battery of in vivo and in vitro testing and found no adverse effects under the conditions tested. In this new work, we present the results of new in vivo and in vitro tests evaluating the safety of LegH Prep. LegH Prep was nonmutagenic in a bacterial reverse mutation assay and nonclastogenic in an in vitro micronucleus assay in human lymphocytes. Systemic toxicity was evaluated in the 90 day dietary study in male and female Sprague–Dawley® rats that included a 28 day recovery period. The study resulted in no animal deaths associated with the administration of LegH Prep at the highest dose (90,000 ppm). There were no significant adverse clinical or physical changes attributed to LegH Prep administration, and no observed adverse effects on either male or female rats over the course of the 28 day recovery phase study. The new 90 day dietary toxicity study established a no observed adverse effect level (NOAEL) of 4798.3 and 5761.5 mg/kg/day, the maximum level tested for male and female rats, respectively. Thus, the results of the studies demonstrate that under the conditions tested, LegH Prep is not toxic for consumption in meat analog products.http://dx.doi.org/10.1155/2023/7398724 |
| spellingShingle | Teresa F. Reyes Puja Agrawal Teresa Chan Richard Green Ray A. Matulka The Safety of Soy Leghemoglobin Protein Preparation Derived from Pichia pastoris Expressing a Soy Leghemoglobin Gene from Glycine max: In Vitro and In Vivo Studies Journal of Toxicology |
| title | The Safety of Soy Leghemoglobin Protein Preparation Derived from Pichia pastoris Expressing a Soy Leghemoglobin Gene from Glycine max: In Vitro and In Vivo Studies |
| title_full | The Safety of Soy Leghemoglobin Protein Preparation Derived from Pichia pastoris Expressing a Soy Leghemoglobin Gene from Glycine max: In Vitro and In Vivo Studies |
| title_fullStr | The Safety of Soy Leghemoglobin Protein Preparation Derived from Pichia pastoris Expressing a Soy Leghemoglobin Gene from Glycine max: In Vitro and In Vivo Studies |
| title_full_unstemmed | The Safety of Soy Leghemoglobin Protein Preparation Derived from Pichia pastoris Expressing a Soy Leghemoglobin Gene from Glycine max: In Vitro and In Vivo Studies |
| title_short | The Safety of Soy Leghemoglobin Protein Preparation Derived from Pichia pastoris Expressing a Soy Leghemoglobin Gene from Glycine max: In Vitro and In Vivo Studies |
| title_sort | safety of soy leghemoglobin protein preparation derived from pichia pastoris expressing a soy leghemoglobin gene from glycine max in vitro and in vivo studies |
| url | http://dx.doi.org/10.1155/2023/7398724 |
| work_keys_str_mv | AT teresafreyes thesafetyofsoyleghemoglobinproteinpreparationderivedfrompichiapastorisexpressingasoyleghemoglobingenefromglycinemaxinvitroandinvivostudies AT pujaagrawal thesafetyofsoyleghemoglobinproteinpreparationderivedfrompichiapastorisexpressingasoyleghemoglobingenefromglycinemaxinvitroandinvivostudies AT teresachan thesafetyofsoyleghemoglobinproteinpreparationderivedfrompichiapastorisexpressingasoyleghemoglobingenefromglycinemaxinvitroandinvivostudies AT richardgreen thesafetyofsoyleghemoglobinproteinpreparationderivedfrompichiapastorisexpressingasoyleghemoglobingenefromglycinemaxinvitroandinvivostudies AT rayamatulka thesafetyofsoyleghemoglobinproteinpreparationderivedfrompichiapastorisexpressingasoyleghemoglobingenefromglycinemaxinvitroandinvivostudies AT teresafreyes safetyofsoyleghemoglobinproteinpreparationderivedfrompichiapastorisexpressingasoyleghemoglobingenefromglycinemaxinvitroandinvivostudies AT pujaagrawal safetyofsoyleghemoglobinproteinpreparationderivedfrompichiapastorisexpressingasoyleghemoglobingenefromglycinemaxinvitroandinvivostudies AT teresachan safetyofsoyleghemoglobinproteinpreparationderivedfrompichiapastorisexpressingasoyleghemoglobingenefromglycinemaxinvitroandinvivostudies AT richardgreen safetyofsoyleghemoglobinproteinpreparationderivedfrompichiapastorisexpressingasoyleghemoglobingenefromglycinemaxinvitroandinvivostudies AT rayamatulka safetyofsoyleghemoglobinproteinpreparationderivedfrompichiapastorisexpressingasoyleghemoglobingenefromglycinemaxinvitroandinvivostudies |